Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares
22.06.2026 - 22:52:29 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 22:48.
Catalyst Pharmaceuticals (US14888U1016) sits under a stable analyst lens this week. The NASDAQ-listed rare-disease developer is covered by a small group of brokers who currently align on a Hold stance with only limited implied upside at current prices.
What the analysts say now
According to data compiled by Public.com, two Wall Street analysts rate Catalyst Pharmaceuticals shares Hold as of June 22, 2026, with zero Buy or Sell recommendations in the sample.Public.com analyst overview The consensus 12-month price target stands at 31.50 US dollars, roughly in line with the latest trading range.
Zacks Investment Research also classifies Catalyst with a Zacks Rank #3, which corresponds to Hold in its five-step system, after the stock added around 0.6 percent since the last earnings release and modestly outperformed the S&P 500 over that period.Zacks commentary on CPRX This keeps the company in a middle-of-the-road position between more defensive and more aggressive sector calls.
Recent earnings and NASDAQ trading level
In its first-quarter 2026 report, Catalyst Pharmaceuticals posted adjusted earnings of 0.79 US dollars per share, beating the Zacks consensus estimate of 0.64 US dollars per share for the period.Zacks Q1 2026 earnings detail The beat adds context to the Hold stance, suggesting expectations were set conservatively.
On June 18, 2026, Catalyst Pharmaceuticals shares closed at 31.38 US dollars on the NASDAQ, with extended-hours trading around 31.37 US dollars shortly after the close, according to MarketBeat data.MarketBeat CPRX quote and profile StockTitan quotes the shares at 31.39 US dollars with a market capitalization near 3.8 billion US dollars and a one-year performance of roughly plus 42 percent as of the afternoon of June 22, 2026.StockTitan snapshot on Catalyst
All news and analysis on the Catalyst Pharmaceuticals shares
Price data, historical performance and further corporate disclosures on Catalyst Pharmaceuticals are available in the dedicated topic section and via the company’s investor-relations site.
How Catalyst earns its money
Catalyst Pharmaceuticals focuses on developing and commercializing medicines for patients with rare neuromuscular and neurological diseases in the United States, operating as a commercial-stage biopharmaceutical company.StockTitan company description Its portfolio centers on in-licensed and internally developed therapies that target serious, often underserved conditions.
Where the stock trades today
The Catalyst Pharmaceuticals shares (US14888U1016) most recently traded on the NASDAQ at 31.39 US dollars on 2026-06-22, 15:17 Eastern time, based on StockTitan data, implying a market capitalization of approximately 3.8 billion US dollars at that point.
Key data on the Catalyst Pharmaceuticals shares
- Company: Catalyst Pharmaceuticals, Inc.
- ISIN: US14888U1016
- WKN: A1W8G0
- Ticker: CPRX
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 15:17): 31.39 USD
- Market cap: 3.8 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: none of the major flagship indices such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Past performance is not a reliable indicator of future results. Readers should conduct their own research and, where appropriate, consult a qualified financial adviser.
